arrow
A

Alok K. Tewari

Harvard Medical School
H指数:20
被引数:3,062

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer

个体内表观遗传异质性是晚期前列腺癌表型亚型的基础

2025-07-010
OAAI
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer

联合固定疗程系统性治疗和转移灶定向放疗治疗寡转移性激素敏感性前列腺癌

2024-11-010
PRE
Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma

II期剂量优化研究,使用EZH2/EZH1抑制剂tulmimetostat治疗携带ARID1A突变的卵巢透明细胞癌患者

2024-09-010
PRE
A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results

一项多队列II期临床试验,研究雄激素剥夺疗法(ADT)、多西他赛(DOCE)和纳武利尤单抗(NIVO)在富集了炎症肿瘤和DNA损伤修复(DDR)改变的新诊断转移性激素敏感性前列腺癌(mHSPC)患者(pts)中的应用:队列3结果

2024-09-010
PRE
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

同时发生的BRCA2/SPOP突变可预测转移性去势抵抗性前列腺癌中特殊的聚 (ADP-核糖) 聚合酶抑制剂敏感性

2024-08-015
PRE
A patient-driven clinicogenomic partnership for metastatic prostate cancer

转移性前列腺癌的患者驱动的临床基因组合作关系

2022-09-011
OAAI
FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance
2021-11-0421
OA
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer
2021-10-0172
OAAI
Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer
2021-09-0129
OAAI
Transcriptional mediators of treatment resistance in lethal prostate cancer
2021-03-04101
OAAI
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

治疗性增加mhc-i表达增强免疫检查点阻断

2021-02-15132
OA